Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Biomol Struct Dyn ; 40(20): 10220-10229, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34139139

RESUMEN

Azoles are first-line drugs used in fungal infections. Topical antifungals, such as miconazole and econazole, are known to be active against Gram-positive bacteria, which was reported to result from bacterial flavohemoglobin (flavoHb) inhibition. Dual antibacterial/antifungal action is believed to have benefits for antimicrobial chemotherapy. In this study, we tested antibacterial effects of an in-house library of naphthalene-bearing azoles, some of which were reported as potent antifungals, in an attempt to find dual-acting hits. Several potent derivatives were obtained against the Gram-positive bacteria, Enterococcus faecalis and Staphylococcus aureus. 9 was active at a minimum inhibitor concentration (MIC) less than 1 µg/ml against E. faecalis and S. aureus, and 10 against S. aureus. 16 was also potent against E. faecalis and S. aureus (MIC = 1 and 2 µg/ml, respectively). Six more were active against S. aureus with MIC ≤ 4 µg/ml. In vitro cytotoxicity studies showed that the active compounds were safe for healthy cells within their MIC ranges. According to the calculated descriptors, the library was found within the drug-like chemical space and free of pan-assay interference compounds (PAINS). Molecular docking studies suggested that the compounds might be bacterial flavohemoglobin (flavoHb) inhibitors and the azole and naphthalene rings were important pharmacophores, which was further supported by pharmacophore modeling study. As a result, the current study presents several non-toxic azole derivatives with antibacterial effects. In addition to their previously reported antifungal properties, they could set a promising starting point for the future design of dual acting antimicrobials. Communicated by Ramaswamy H. Sarma.


Asunto(s)
Antiinfecciosos , Staphylococcus aureus , Antifúngicos/farmacología , Azoles , Simulación del Acoplamiento Molecular , Bacterias Grampositivas , Antibacterianos/farmacología , Antibacterianos/química , Antiinfecciosos/farmacología , Naftalenos/farmacología , Pruebas de Sensibilidad Microbiana
2.
Int Microbiol ; 24(1): 93-102, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-32889579

RESUMEN

Candida infections pose a serious public health threat due to increasing drug resistance. Azoles are first-line antifungal drugs for fungal infections. In this study, we tested an in-house azole collection incorporating naphthalene ring to find hits against planktonic and biofilm forms of resistant Candida spp. In the collection, potent derivatives were identified against the susceptible strains of Candida with minimum inhibitory concentration (MIC) values lower than those of the reference drug, fluconazole. MIC values of 0.125 µg/ml against C. albicans, 0.0625 µg/ml against C. parapsilosis, and 2 µg/ml against C. krusei, an intrinsically azole-resistant non-albicans Candida, were obtained. Some of the derivatives were highly active against fluconazole-resistant clinical isolate of C. tropicalis. Inhibition of C. albicans biofilms was also observed at 4 µg/ml similar as amphotericin B, the reference drug known for its antibiofilm activity. Through molecular docking studies, affinities and key interactions of the compounds with fungal lanosterol 14α-demethylase (CYP51), the target enzyme of azoles, were predicted. The interactions of imidazole with heme cofactor and of the naphthalene with Tyr118 were highlighted in line with the literature data. As a result, this study proves the importance of naphthalene for the antifungal activity of azoles against Candida spp. in both planktonic and biofilm forms.


Asunto(s)
Antifúngicos/farmacología , Azoles/farmacología , Biopelículas/efectos de los fármacos , Candida/efectos de los fármacos , Candidiasis/microbiología , Antifúngicos/química , Azoles/química , Candida/genética , Candida/fisiología , Candidiasis/tratamiento farmacológico , Farmacorresistencia Fúngica , Humanos , Pruebas de Sensibilidad Microbiana , Naftalenos/química , Naftalenos/farmacología , Plancton/efectos de los fármacos , Plancton/genética , Plancton/fisiología
3.
Eur J Med Chem ; 57: 275-82, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23085104

RESUMEN

Twenty-three new oxime ester derivatives of nafimidone were synthesized with the prospect of potential anticonvulsant activities. MES and ScM tests were employed for their anticonvulsant activities and rotorod test for neurological deficits. Eighteen compounds were found to be protective against MES seizures. Alkyl (1-8) and arylalkyl (9, 10) oxime ester derivatives were found to be more active than aryl oxime ester derivatives (11-23). Five compounds (2, 3, 7, 9, 10), which were protective at 0.5 h at the doses of 30 mg/kg and higher in MES test, showed the highest activity. Compound 17 was the most active one in ScM test at all dose levels at 4 h.


Asunto(s)
Anticonvulsivantes/síntesis química , Imidazoles/síntesis química , Nafazolina/análogos & derivados , Oximas/síntesis química , Convulsiones/prevención & control , Animales , Anticonvulsivantes/farmacología , Electrochoque , Ésteres , Imidazoles/farmacología , Isomerismo , Ratones , Actividad Motora/efectos de los fármacos , Nafazolina/química , Nafazolina/farmacología , Pruebas Neuropsicológicas , Oximas/farmacología , Convulsiones/fisiopatología , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA